ATRX and leukemia: To test if the combinations of Polθi and ADH5i or ALDHi may have potential clinical applications, SCID-beige mice bearing Nalm6-RAD54−/− leukemia were treated with RP-6685, a potent, selective, and orally bioavailable Polθi [47] alone and in combination with disulfiram or N6022 for 14 consecutive days (Fig. 5E).